Press Releases
Year-end Report 1 January to 31 December 2022
17 Feb, 2023 08:30 CETRegulatoryCyxone receive ethical and regulatory approval from Georgia to conduct clinical Phase 2b study in RA
9 Feb, 2023 12:20 CETCyxone advances the patent portfolio for Rabeximod
6 Feb, 2023 12:14 CETCyxone appoints Carl-Magnus Högerkorp as permanent CEO
13 Dec, 2022 13:10 CETRegulatoryCyxone receive ethical and regulatory approval from Hungary to start clinical Phase 2b study in RA
1 Dec, 2022 10:56 CET